Quarterly ResultAug 10, 2026, 04:19 PM
Olema Q2 Net Loss $(63.2)M; R&D Expenses Up 31.6%
AI Summary
Olema Pharmaceuticals reported a net loss of $(63.2) million for Q2 2026, an increase from $(43.8) million in Q2 2025. Research and development expenses rose significantly to $57.8 million, up 31.6% year-over-year. For the first six months of 2026, the net loss was $(116.3) million, with R&D expenses at $107.0 million. The company raised $41.9 million through an at-the-market offering during the first half of 2026 and believes its current liquidity is sufficient for at least the next 12 months.
Key Highlights
- Q2 2026 net loss was $(63.2) million, compared to $(43.8) million in Q2 2025.
- Q2 2026 research and development expenses increased 31.6% to $57.8 million.
- Net loss per share for Q2 2026 was $(0.61), up from $(0.51) in Q2 2025.
- Net loss for the six months ended June 30, 2026, was $(116.3) million.
- Net cash used in operating activities for H1 2026 was $(91.9) million.
- Issued 1.71 million common shares via ATM offering for $41.9 million net proceeds in H1 2026.
- Total cash, cash equivalents, and marketable securities stood at $461.1 million as of June 30, 2026.
- Management believes current liquidity is sufficient for at least the next 12 months.
Price Impact
More from OLMA